Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5075226 | 0.99 | AURKA (0.52) | AURKAAURKBHRH3MAPK7KDM4E | |
| SCHEMBL5138448 | 0.95 | MAPK7 (0.49) | AURKAAURKBHRH3MAPK7KDM4E | |
| SCHEMBL4963778 | 0.92 | AURKA (0.52) | AURKAAURKBHRH3MAPK7KCNH2 | |
| SCHEMBL4965030 | 0.91 | AURKA (0.53) | AURKAAURKBHRH3MAPK7KCNH2 | |
| SCHEMBL4966697 | 0.91 | AURKA (0.53) | AURKAAURKBMAPK7MAOB | |
| SCHEMBL4964489 | 0.91 | MAPK7 (0.49) | AURKAAURKBMAPK7 | |
| SCHEMBL4964964 | 0.91 | CHEK1 (0.54) | AURKAAURKBHRH3MAPK7KCNH2 | |
| SCHEMBL4964717 | 0.91 | CHEK1 (0.48) | AURKAAURKBMAPK7ALDH1A1SMN1; SMN2 | |
| SCHEMBL4962333 | 0.90 | MAPK7 (0.48) | AURKAAURKBHRH3MAPK7MAOB | |
| SCHEMBL4962787 | 0.87 | MAPK7 (0.46) | AURKAAURKBHRH3MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | FLT3, KIT, NTRK2 | AURKA 94/4885AURKB 44/4885HRH3 1117/4885 |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | AURKA 174/4885AURKB 41/4885HRH3 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.